Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 9664.121 | 1.0434 | 1.1200 | 0.7294 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 9664.121 | 1.0559 | 1.1550 | 0.7294 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9664.121 | 0.9846 | 0.9578 | 0.7294 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9664.121 | 1.0219 | 1.0604 | 0.7294 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9664.121 | 0.4152 | -0.4008 | 0.7294 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9664.121 | 0.2704 | -0.6672 | 0.7294 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9664.121 | 0.1260 | -0.8832 | 0.7294 | |
| MDA-MB-415 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 92 | uM | 9664.121 | 0.0008 | -0.9999 | 0.7294 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 7899.077 | 1.0958 | 1.0852 | 2.1925 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 7899.077 | 0.9537 | 0.9573 | 2.1925 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 7899.077 | 1.0807 | 1.0721 | 2.1925 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 7899.077 | 0.9013 | 0.9074 | 2.1925 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.147 | uM | 7899.077 | 0.9307 | 0.9355 | 2.1925 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.736 | uM | 7899.077 | 0.4884 | 0.4423 | 2.1925 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.68 | uM | 7899.077 | 0.3661 | 0.2646 | 2.1925 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 18.4 | uM | 7899.077 | 0.3895 | 0.3009 | 2.1925 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 92 | uM | 7899.077 | 0.2738 | 0.1078 | 2.1925 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 10266.121 | 1.1974 | 1.5768 | 0.7110 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 10266.121 | 0.9479 | 0.8550 | 0.7110 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 10266.121 | 1.1922 | 1.5610 | 0.7110 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 10266.121 | 0.9952 | 0.9866 | 0.7110 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.147 | uM | 10266.121 | 1.1036 | 1.2975 | 0.7110 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.736 | uM | 10266.121 | 0.6506 | 0.0927 | 0.7110 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.68 | uM | 10266.121 | 0.4497 | -0.3500 | 0.7110 | |
| MDA-MB-436 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 18.4 | uM | 10266.121 | 0.5137 | -0.2163 | 0.7110 |